Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study

Ping Zhou,Bing Liu,Ning Shen,Xiaoting Fan,Shangwei Lu,Zhijuan Kong,Ying Gao,Zhimei Lv,Rong Wang
DOI: https://doi.org/10.1080/0886022x.2024.2326186
IF: 3.222
2024-03-13
Renal Failure
Abstract:Background Immune checkpoint inhibitor-associated acute kidney injury (ICI-AKI) is the most common renal complication and has attracted increasing amounts of attention. However, studies on this topic in Chinese cancer patients are very limited. Therefore, we conducted a retrospective study on the incidence, risk factors, clinical features and renal recovery of ICI-AKI in all patients with malignancies treated with ICIs in Shandong Provincial Hospital Affiliated to Shandong First Medical University.
urology & nephrology
What problem does this paper attempt to address?
The paper aims to explore the incidence, risk factors, clinical characteristics, and renal function recovery of immune checkpoint inhibitor (ICI)-related acute kidney injury (ICI-AKI) in Chinese cancer patients. Specifically: 1. **Research Background**: Immune checkpoint inhibitors (ICIs) have been widely used as an anti-tumor treatment for various advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, and melanoma. However, ICIs may also cause the immune system to lose tolerance to self-antigens, leading to immune-related adverse events (irAEs), among which acute kidney injury (AKI) is one of the most common renal complications. 2. **Research Objective**: Given the limited research on ICI-AKI in China, this study conducts a retrospective analysis of cancer patients treated with ICIs at Shandong Provincial Hospital affiliated with Shandong First Medical University. The aim is to explore the incidence, risk factors, and prognosis of ICI-AKI, thereby providing references for the diagnosis and management of this disease and enhancing the understanding of renal complications during anti-tumor treatment. In summary, the main objective of this paper is to systematically evaluate the incidence, risk factors, and renal function recovery of ICI-AKI in Chinese cancer patients treated with ICIs through a single-center retrospective study.